Gelesis

69 articles about Gelesis

• Gelesis Presents Expanded Data Showing Impact of Gelesis100 Hydrogel on Patients with Prediabetes, Untreated Diabetes, and Elevated Insulin Resistance

  3/25/2019

  Individuals with prediabetes and those with untreated type 2 diabetes had six times higher odds to achieve ≥10% weight loss compared to placebo

• Gelesis Announces Three Presentations at Annual Endocrine Society Meeting

  3/21/2019

  Gelesis announced the Company will deliver three poster presentations at ENDO, the Endocrine Society Annual Meeting, held in New Orleans from March 23-26.

• Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018

  11/5/2018

  Gelesis today announced that the Company will deliver an oral presentation and three poster presentations at ObesityWeek 2018, the annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society in Nashville, Tennessee, from November 11-15, 2018.

• Harry Leider, Former Chief Medical Officer of Walgreens, Joins Gelesis as Chief Medical Officer, and Paul Fonteyne, Chairman and Former CEO of Boehringer Ingelheim USA, Joins the Gelesis Board of Directors

  6/5/2018

  New appointees bring extensive medical and commercial expertise to Gelesis as the company prepares for regulatory approval filings in the U.S. and Europe

• 

  VCs Are Pouring Billions into Biotech in 2018

  3/6/2018

  While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
• 

  Gelesis Secures $30 Million to Support Potential Approval of Weight Loss Drug

  3/1/2018

  Boston-based Gelesis snagged $30 million to support potential manufacturing and commercialization of its anti-obesity drug.

• Gelesis Raises $30 Million to Prepare for Potential Launch of Lead Product

  3/1/2018

  Proceeds to be used for manufacturing and commercialization preparations and advancement of the Company’s clinical development pipeline

• Gelesis100 Achieves Significant Weight Loss With Excellent Safety Profile In Pivotal Study

  9/25/2017

• Gelesis Announces Last Patient Out In The Pivotal Gelesis100 Weight-Loss Study

  7/12/2017

• GelesisAnnounces €2.9 Million Award From Italian Ministry Of Economic Development

  5/3/2017

• Gelesis Release: Administration Of Gelesis200 Increases Fullness And Satiety In People Who Are Overweight Or Have Obesity

  11/4/2016

• Gelesis Appoints New Chief Operating Officer

  9/2/2016

• Gelesis Announces Positive Safety Data From First-In-Human Study Of Second Product Candidate, Gelesis200

  5/3/2016

• Gelesis Announces First U.S. Patient Enrolled In Pivotal Gelesis100 Weight-Loss Study

  4/26/2016

• Boston's Gelesis Banks $31.5 Million Growth Financing

  12/18/2015

• Gelesis Expands Ongoing Weight Loss Study To Serve As U.S. Pivotal Trial, Significantly Accelerating Development Timeline

  7/27/2015

• Gelesis Expands Ongoing Weight Loss Study To Serve As U.S. Pivotal Trial, Significantly Accelerating Development Timeline

  7/27/2015

• Gelesis Presents Additional Data At European Congress On Obesity

  5/22/2015

• With $22 Million in Hand, Gelesis Files for $60 Million IPO

  4/3/2015

• Gelesis Reels in $22M More, Increases Clinical Trials for Gelesis100

  3/26/2015